Key facts
- Sen-Jam Pharmaceutical’s last known valuation is $80.0M (Apr 2025).
- It has raised $15.2M across 1 recorded rounds; the latest was Seed Round ($295K) in Apr 2023.
- Notable investors include 5 Horizons Capital, Dipika Ghosal, George Czajkowsk, Opus8, Richard Goldberg.
- Sen-Jam Pharmaceutical has filed 4 Form Ds with the SEC since 2020, most recently Jul 2024 ($295K sold to 6 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Sen-Jam Pharmaceutical
Funding rounds
1 roundsAbout Sen-Jam Pharmaceutical
Operator of a biotech company intended to treat inflammation and metabolic disorders. The company's drugs stabilize the innate immune system while reducing inflammation intracellularly, helping the patient's body to maintain homeostasis, products treat acute inflammation due to upper respiratory infections, alcohol's inflammatory effects, and vaccination administration, enabling healthcare providers to improve the lives of the patients and global accessibility.
- Sector
- Healthcare
- HQ
- Huntington, NY, United States
- Founded
- 2017
- Employees
- 8
- Website
- sen-jam.com/
- Ownership
- Privately Held (backing)
Sen-Jam Pharmaceutical doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Sen-Jam Pharmaceutical shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Sen-Jam Pharmaceutical in its N-PORT filings yet. We sweep new filings monthly.